哮喘对慢性鼻窦炎伴鼻息肉手术成本效果的影响
本研究采用35年时间跨度的队列式马尔可夫决策树成本效用分析,比较伴哮喘(n=95)与不伴哮喘(n=95)的CRSwNP患者接受ESS与药物治疗的成本效果。结果显示,伴哮喘与不伴哮喘患者的ICER分别为每QALY 12,066美元和7,369美元;在50,000美元/QALY支付意愿阈值下,ESS为最具成本效果策略的确定性分别为86%和99%。结论认为ESS对两类患者均具成本效果,哮喘虽使ICER变差但无统计学显著负面影响。
要点
- 伴哮喘CRSwNP患者ESS的ICER为每QALY 12,066美元,不伴哮喘者为7,369美元。
- 在50,000美元/QALY阈值下,ESS具成本效果的确定性分别为86%和99%。
- 哮喘合并症使ICER变差,但对ESS总体成本效果无统计学显著负面影响。
核心结论
- ESS与药物治疗相比,对伴哮喘和不伴哮喘的CRSwNP患者均具成本效果。
- 哮喘合并症导致ICER结果较差,但未对ESS总体成本效果产生统计学显著负面影响。
研究设计与样本
- 研究设计为队列式马尔可夫决策树成本效用分析,时间跨度为35年。
- 匹配队列包括伴哮喘(n=95)和不伴哮喘(n=95)的CRSwNP患者,均接受ESS。
- 对照队列来自全国医疗支出调查面板(MEPS)数据库,接受慢性鼻窦炎(CRS)药物治疗。
- 基线、1年和2年健康效用值通过EuroQol-5 Dimension(EQ-5D)问卷计算。
- 主要结局指标为各队列的增量成本效果比(ICER)。
主要发现
- 伴哮喘CRSwNP患者ESS对比单纯药物治疗的ICER为每质量调整生命年(QALY)12,066美元。
- 不伴哮喘CRSwNP患者ESS对比单纯药物治疗的ICER为每QALY 7,369美元。
- 在50,000美元/QALY支付意愿阈值下,ICER散点图显示ESS为最具成本效果策略的确定性在伴哮喘和不伴哮喘患者中分别为86%和99%。
- ESS对不伴哮喘的CRSwNP患者并未显著更具成本效果(p = 0.494)。
关键数值与推荐
- 伴哮喘CRSwNP患者ESS的ICER为每QALY 12,066美元。
- 不伴哮喘CRSwNP患者ESS的ICER为每QALY 7,369美元。
- 支付意愿阈值为50,000美元/QALY时,ESS具成本效果的确定性分别为86%(伴哮喘)和99%(不伴哮喘)。
- ESS对不伴哮喘患者的成本效果比较p = 0.494。
临床怎么用
- 对于伴或不伴哮喘的CRSwNP患者,ESS均可作为具有成本效果的治療选择。
- 哮喘合并症虽使ICER升高,但不构成排除ESS的成本效果理由。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this work was to evaluate the impact of asthma on the cost-effectiveness profile of endoscopic sinus surgery (ESS) compared to medical therapy for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). METHODS: The study design consisted of a cohort-style Markov decision-tree cost utility analysis with a 35-year time horizon. Matched cohorts of CRSwNP patients with (n = 95) and without (n = 95) asthma who underwent ESS were compared with cohorts of patients from the national Medical Expenditures Survey Panel (MEPS) database who underwent medical management for chronic rhinosinusitis (CRS). Baseline, 1-year, and 2-year health utility values were calculated from responses to the EuroQol-5 Dimension (EQ-5D) instrument in both cohorts. The primary outcome measure was the incremental cost effectiveness ratio (ICER) for each cohort. RESULTS: The reference cases for CRSwNP patients with and without asthma yielded ICERs for ESS vs medical therapy alone of $12,066 per quality-adjusted life year (QALY) and $7,369 per QALY, respectively. At a willingness-to-pay threshold of $50,000/QALY, the ICER scatter plots demonstrated 86% and 99% certainty that the ESS strategy was the most cost-effective option for CRSwNP patients with and without asthma, respectively. ESS was not significantly more cost effective for CRSwNP patients without asthma (p = 0.494). CONCLUSION: ESS remains cost effective compared to medical therapy for patients both with and without asthma. While the comorbidity of asthma results in an inferior ICER result, it does not result in a statistically significant negative impact on the overall cost effectiveness of ESS.
引用
- Scangas GA, Remenschneider AK, Su BM, et al. The impact of asthma on the cost effectiveness of surgery for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2017. PMID: 28873286. doi:10.1002/alr.22013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。